Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- ADMA
- Price
- 17.40
- Stock movement up
- +0.04 (0.23%)
- Company name
- ADMA Biologics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 4.14B
- Ent value
- 4.22B
- Price/Sales
- 8.48
- Price/Book
- 9.60
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 19.77
- Forward P/E
- 18.51
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- 7.67%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ADMA does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 19.77 |
| Price to OCF | 63.74 |
| Price to FCF | 101.67 |
| Price to EBITDA | 34.25 |
| EV to EBITDA | 34.88 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 8.48 |
| Price to Book | 9.60 |
| EV to Sales | 8.63 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 238.00M |
| EPS (TTM) | 0.86 |
| FCF per share (TTM) | 0.17 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 488.56M |
| Gross profit (TTM) | 267.28M |
| Operating income (TTM) | 167.01M |
| Net income (TTM) | 209.45M |
| EPS (TTM) | 0.86 |
| EPS (1y forward) | 0.94 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 54.71% |
| Operating margin (TTM) | 34.19% |
| Profit margin (TTM) | 42.87% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 61.38M |
| Net receivables | 137.67M |
| Total current assets | 402.65M |
| Goodwill | 3.53M |
| Intangible assets | 491.00K |
| Property, plant and equipment | 78.78M |
| Total assets | 568.69M |
| Accounts payable | 24.02M |
| Short/Current long term debt | 83.12M |
| Total current liabilities | 56.49M |
| Total liabilities | 137.50M |
| Shareholder's equity | 431.19M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 64.97M |
| Capital expenditures (TTM) | 24.25M |
| Free cash flow (TTM) | 40.73M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 48.57% |
| Return on Assets | 36.83% |
| Return on Invested Capital | 48.17% |
| Cash Return on Invested Capital | 9.37% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 17.33 |
| Daily high | 17.79 |
| Daily low | 17.24 |
| Daily Volume | 2.26M |
| All-time high | 24.51 |
| 1y analyst estimate | 25.67 |
| Beta | 0.43 |
| EPS (TTM) | 0.86 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 19 Mar 2026 |
Downside potential
Loading...
Downside potential data
| ADMA | S&P500 | |
| Current price drop from All-time high | -29.01% | -0.89% |
| Highest price drop | -42.92% | -19.00% |
| Date of highest drop | 7 Oct 2025 | 8 Apr 2025 |
| Avg drop from high | -23.25% | -2.49% |
| Avg time to new high | 161 days | 6 days |
| Max time to new high | 186 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
4.14B
Marketcap category
Mid-cap
Description
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Employees
677
Investor relations
-
SEC filings
CEO
Adam S. Grossman
Country
USA
City
Ramsey
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page